FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021805215> ?p ?o ?g. }

• W2021805215 endingPage "6750" @default.
• W2021805215 startingPage "6738" @default.
• W2021805215 abstract "The hypoxia inducible factor (HIF) pathway is an attractive target for cancer, as it controls tumor adaptation to growth under hypoxia and mediates chemotherapy and radiation resistance. We previously discovered 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide as a novel, small-molecule HIF-1 pathway inhibitor in a high-throughput cell-based assay, but its in vivo delivery is hampered by poor aqueous solubility (0.009 μM in water; log P(7.4) = 3.7). Here we describe the synthesis of 12 N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, which were designed to possess optimal lipophilicities and aqueous solubilities by in silico calculations. Experimental log P(7.4) values of 8 of the 12 new analogs ranged from 1.2-3.1. Aqueous solubilities of three analogs were measured, among which the most soluble N-[(8-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl]-N-(propan-2-yl)pyridine-2-sulfonamide had an aqueous solubility of 80 μM, e.g., a solubility improvement of ∼9000-fold. The pharmacological optimization had limited impact on drug efficacy as the compounds retained IC(50) values at or below 5 μM in our HIF-dependent reporter assay." @default.
• W2021805215 created "2016-06-24" @default.
• W2021805215 creator A5008303358 @default.
• W2021805215 creator A5019118611 @default.
• W2021805215 creator A5036023937 @default.
• W2021805215 creator A5048772498 @default.
• W2021805215 creator A5057082646 @default.
• W2021805215 creator A5057999303 @default.
• W2021805215 creator A5064487613 @default.
• W2021805215 creator A5067459058 @default.
• W2021805215 creator A5071096198 @default.
• W2021805215 creator A5089781267 @default.
• W2021805215 date "2012-07-24" @default.
• W2021805215 modified "2023-10-18" @default.
• W2021805215 title "Design and in Vitro Activities of<i>N</i>-Alkyl-<i>N</i>-[(8-<i>R</i>-2,2-dimethyl-2<i>H</i>-chromen-6-yl)methyl]heteroarylsulfonamides, Novel, Small-Molecule Hypoxia Inducible Factor-1 Pathway Inhibitors and Anticancer Agents" @default.
• W2021805215 cites W1541037889 @default.
• W2021805215 cites W1578283200 @default.
• W2021805215 cites W1969073798 @default.
• W2021805215 cites W1972944556 @default.
• W2021805215 cites W1974029411 @default.
• W2021805215 cites W1977242675 @default.
• W2021805215 cites W1980016018 @default.
• W2021805215 cites W1980966996 @default.
• W2021805215 cites W1981938712 @default.
• W2021805215 cites W1988692970 @default.
• W2021805215 cites W1989162648 @default.
• W2021805215 cites W1998664010 @default.
• W2021805215 cites W2001288003 @default.
• W2021805215 cites W2002942874 @default.
• W2021805215 cites W2003848135 @default.
• W2021805215 cites W2004941068 @default.
• W2021805215 cites W2009453429 @default.
• W2021805215 cites W2011810742 @default.
• W2021805215 cites W2024486369 @default.
• W2021805215 cites W2025370055 @default.
• W2021805215 cites W2027542963 @default.
• W2021805215 cites W2027806414 @default.
• W2021805215 cites W2029968342 @default.
• W2021805215 cites W2039075677 @default.
• W2021805215 cites W2040960639 @default.
• W2021805215 cites W2045579425 @default.
• W2021805215 cites W2045710215 @default.
• W2021805215 cites W2052566306 @default.
• W2021805215 cites W2053036921 @default.
• W2021805215 cites W2053443882 @default.
• W2021805215 cites W2053621712 @default.
• W2021805215 cites W2068950612 @default.
• W2021805215 cites W2070608335 @default.
• W2021805215 cites W2071551353 @default.
• W2021805215 cites W2073132333 @default.
• W2021805215 cites W2075880922 @default.
• W2021805215 cites W2083098015 @default.
• W2021805215 cites W2087147922 @default.
• W2021805215 cites W2092386950 @default.
• W2021805215 cites W2093175395 @default.
• W2021805215 cites W2094836090 @default.
• W2021805215 cites W2104381279 @default.
• W2021805215 cites W2105294528 @default.
• W2021805215 cites W2109415128 @default.
• W2021805215 cites W2111527534 @default.
• W2021805215 cites W2127096730 @default.
• W2021805215 cites W2139237193 @default.
• W2021805215 cites W2140009766 @default.
• W2021805215 cites W2140102023 @default.
• W2021805215 cites W2143643440 @default.
• W2021805215 cites W2152098789 @default.
• W2021805215 cites W2153223436 @default.
• W2021805215 cites W2155643508 @default.
• W2021805215 cites W2161336519 @default.
• W2021805215 cites W2163572677 @default.
• W2021805215 cites W2164901739 @default.
• W2021805215 cites W2167104992 @default.
• W2021805215 cites W2330496546 @default.
• W2021805215 cites W2949177903 @default.
• W2021805215 cites W2949533239 @default.
• W2021805215 cites W3022256396 @default.
• W2021805215 doi "https://doi.org/10.1021/jm300752n" @default.
• W2021805215 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3756490" @default.
• W2021805215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22746274" @default.
• W2021805215 hasPublicationYear "2012" @default.
• W2021805215 type Work @default.
• W2021805215 sameAs 2021805215 @default.
• W2021805215 citedByCount "46" @default.
• W2021805215 countsByYear W20218052152012 @default.
• W2021805215 countsByYear W20218052152013 @default.
• W2021805215 countsByYear W20218052152014 @default.
• W2021805215 countsByYear W20218052152015 @default.
• W2021805215 countsByYear W20218052152016 @default.
• W2021805215 countsByYear W20218052152017 @default.
• W2021805215 countsByYear W20218052152018 @default.
• W2021805215 countsByYear W20218052152019 @default.
• W2021805215 countsByYear W20218052152020 @default.
• W2021805215 countsByYear W20218052152021 @default.
• W2021805215 countsByYear W20218052152022 @default.
• W2021805215 countsByYear W20218052152023 @default.
• W2021805215 crossrefType "journal-article" @default.
• W2021805215 hasAuthorship W2021805215A5008303358 @default.
• W2021805215 hasAuthorship W2021805215A5019118611 @default.

• next